H.C. Wainwright raised the firm’s price target on CymaBay to $21 from $19 and keeps a Buy rating on the shares post the Q2 report. The analyst says the IDEAL study is set to challenge the current benchmark and reset expectations for second line treatment in primary biliary cholangitis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CBAY: